Peripheral Nerve Sheath Tumor - Healing Genes

Peripheral Nerve Sheath Tumor

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Vaccine Therapy in Treating Patients With Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery

Phase I Trial of Intratumoral Administration of a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Unresectable or Recurrent Malignant Peripheral Nerve Sheath Tumor

Phase 1


Doctors at the Mayo Clinic in MN seek patients with malignant peripheral nerve sheath tumor that cannot be removed by surgery (unresectable) or has come back after a period of improvement (recurrent) to trial a therapeutic vaccine. This vaccine contains a genetically engineered virus designed to target tumors. Other eligible tumors: Neurofibromatosis Type 1

The virus is a modified version of the measles virus used to vaccinate children. The virus has been altered by having an extra gene (piece of DNA) added to it that helps the body concentrate iodine. Having this additional gene will make it possible to track where the virus goes in the body, through a scan a few days after the injection of the drug to the tumor.


  • Be 18 years of age and older
  • Not be pregnant or breastfeeding
  • Meet lab assessment requirements for overall health status
  • Allergy to measles vaccine or history of severe reaction to prior measles vaccination


  1. Screening to confirm acceptance to the study.
  2. Intratumoral (into the tumor) injection of the vaccine.
  3. Undergo PET scans over the next 30 days and at 6 weeks.
  4. Follow up will continue for up to 2 years


The study will take place at Mayo Clinic in Rochester in Rochester, MN, Map.


Mayo Clinical Trials Referral Office  |  855-776-0015




Mayo Clinic

National Cancer Institute (NCI)


Or go online:

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader